Document is current
Any future updates will be listed below
-
Authors
García-Torralba, Esmeralda https://orcid.org/0000-0002-3744-2182
Loi, Sherene https://orcid.org/0000-0001-6137-9171
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
Buqué, Aitziber
- License Information
-
More Information
Article History
Accepted: 21 April 2026
First Online: 18 May 2026
Competing interests
: S.L. is/has been holding research contracts with Novartis, Bristol Myers Squibb, AstraZeneca/Daiichi Sankyo, Roche-Genentech, MSD, Pfizer, Gilead Sciences, Nektar Therapeutics and Eli Lilly; and has received consulting/advisory honoraria from Roche-Genentech, MSD, Gilead Sciences, AstraZeneca/Daiichi Sankyo, Bristol Myers Squibb, Novartis, Eli Lilly, Amaroq Therapeutics, Mersana Therapeutics, Domain Therapeutics, BioNTech, Bicycle Therapeutics, Exact Sciences, Menari Asia-Pacific, SAGA Diagnostics and Adanate. R.S. is/has been holding research contracts with Roche, Puma, Merck and BMS; has received consulting/advisory honoraria from BMS, Roche, AstraZeneca, Daichii Sankyo and Exact Sciences; is a member of an advisory group to the Belgian Government on reimbursement of assays in genomics and pathology; and is co-chair of The International Immuno-Oncology Biomarker Working Group ( ). L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo; has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom and the Luke Heller TECPR2 Foundation; and holds Promontory stock options. E.G.-T. and A.B. declare no competing interests.
